Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
Type:
Grant
Filed:
May 6, 2010
Date of Patent:
October 29, 2013
Assignee:
CSL Limited
Inventors:
Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
Abstract: A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises administration, preferably parenteral administration, to the patient of an effective amount of high density lipoprotein (HDL).
Abstract: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.
Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.
Type:
Grant
Filed:
February 17, 2011
Date of Patent:
September 17, 2013
Assignee:
CSL Limited
Inventors:
Gino Luigi Vairo, Andrew Nash, Eugene Maraskovsky, Nick Wilson, Samantha Busfield
Abstract: A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.
Type:
Application
Filed:
December 4, 2012
Publication date:
September 5, 2013
Applicants:
University Health Network, CSL Limited
Inventors:
John Edgar Dick, Liqing Jin, Gino Luigi Vairo, David Paul Gearing, Samantha Jane Busfield
Abstract: The present invention relates generally to the field of cancer therapy. More particularly, the present invention provides a method for the treatment of gastrointestinal-type cancers and therapeutic agents useful for same.
Type:
Grant
Filed:
October 14, 2009
Date of Patent:
August 27, 2013
Assignees:
CSL Limited, Ludwig Institute for Cancer Research Ltd.
Inventors:
Brendan J. Jenkins, Tracy Lynn Putoczki, Matthias Ernst, Andrew Jarnicki, Brent McKenzie
Abstract: A method for treating or preventing an inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a compound that inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) signaling.
Abstract: A method of preparing anti-b amyloid immunoglobulin involves treating human plasma anti-b amyloid immunoglobulin under alkaline conditions, such as at pH 10.25 to 11.75 using diethylamine HCl, to dissociate b amyloid protein therefrom. Typically, the anti-b amyloid immunoglobulin is present in human immunoglobulin preparations obtained from plasma or serum. Anti-b amyloid immunoglobulin prepared by the method is substantially free of b amyloid protein and has therapeutic activity in compositions and/or methods for treating a disease or condition associated with b amyloid plaques, such as Alzheimer's disease.
Abstract: A method for the treatment of a condition which is characterized by CD 123-expressing cells in a patient comprises administering to the patient (i) an antibody or antibody fragment which binds selectively to IL-3R?(CD 123), and (ii) an immunostimulating complex which comprises saponin, a sterol and a phospholipid.
Type:
Application
Filed:
June 15, 2011
Publication date:
June 13, 2013
Applicant:
CSL LIMITED
Inventors:
Debra Pauline Drane, Eugene Maraskovsky, Jefferey Stephen Boyle
Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.
Type:
Application
Filed:
February 17, 2011
Publication date:
April 4, 2013
Applicant:
CSL Limited
Inventors:
Gino Luigi Vairo, Andrew Nash, Eugene Maraskovsky, Nick Wilson, Samantha Busfield
Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
Type:
Application
Filed:
June 13, 2012
Publication date:
December 20, 2012
Applicant:
CSL LIMITED
Inventors:
Andrew Donald NASH, Arna Elizabeth ANDREWS, Manuel BACA, Kirsten Mae EDWARDS, Matthew Philip HARDY, Con PANOUSIS, Felicity Meredith DUNLOP
Abstract: The invention encompasses the use of one or more compounds selected from a list comprising i) reduced forms of vitamin K and/or ii) reduced forms of a vitamin K analog and/or iii) reduced forms of a vitamin K precursor for the expression of one or more functional vitamin K-dependent proteins in cell culture as well as processes for the fermentation of eucaryotic cells expressing one or more vitamin K-dependent proteins wherein one or more compounds selected from a list comprising i) reduced forms of vitamin K and/or ii) reduced forms of a vitamin K analog and/or iii) reduced forms of a vitamin K precursor are added to the cell culture medium before and/or during the fermentation process.
Type:
Application
Filed:
July 9, 2010
Publication date:
December 20, 2012
Applicant:
CSL LIMITED
Inventors:
Julian Keane, Anthony Stowers, Peter Soupourmas, Fraser Goodwin
Abstract: The present invention provides an antigenic composition, the composition comprising at least one recombinant protein. The recombinant protein comprises at least one epitope. The epitope is reactive with an antibody which is reactive with a polypeptide having the sequence set out in SEQ. ID. NO. 3 or SEQ. ID. NO. 5. The invention also provides methods and compositions for the production of the recombinant protein. Also provided are methods for the diagnosis, treatment and prevention of P. gingivalis infection.
Type:
Grant
Filed:
March 27, 2007
Date of Patent:
October 9, 2012
Assignee:
CSL Limited
Inventors:
Eric C. Reynolds, Nada Slakeski, Guang Gao Chen, George Ian Barr
Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.
Type:
Application
Filed:
October 1, 2010
Publication date:
September 27, 2012
Applicant:
CSL LIMITED
Inventors:
Devendra Keshaorao Hiwase, Timothy Peter Hughes, Angel Francisco Lopez, Gino Luigi Vairo
Abstract: Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R? activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
Type:
Grant
Filed:
October 19, 2007
Date of Patent:
June 26, 2012
Assignee:
CSL Limited
Inventors:
Andrew Donald Nash, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
Abstract: The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.
Type:
Grant
Filed:
October 23, 2008
Date of Patent:
May 22, 2012
Assignees:
CSL Limited, Yale University
Inventors:
Manuel Baca, Andrew Donald Nash, Jack A. Elias
Abstract: The present invention relates generally to an immunogenic complex comprising a charged organic carrier and a charged antigen and, more particularly, a negatively charged organic carrier and a positively charged antigen. The complexes of the present invention are useful, inter alia, as therapeutic and/or prophylactic agents for facilitating the induction of a cytotoxic T-lymphocyte response to an antigen.
Type:
Grant
Filed:
July 1, 2009
Date of Patent:
May 8, 2012
Assignee:
CSL Limited
Inventors:
John Cooper Cox, Debbie Pauline Drane, Andreas Suhrbier
Abstract: The present invention relates to isolated Porphyromonas gingivalis polypeptides and nucleotides. The polypeptides include an amino acid sequence selected from the group consisting of: SEQ. ID. NO. 110; SEQ. ID. NO. 111; SEQ. ID. NO. 112; SEQ. ID. NO. 113; SEQ ID NO: 120; SEQ. ID. NO. 123; SEQ. ID. NO. 124; SEQ. ID. NO. 125; SEQ. ID. NO. 130; SEQ. ID. NO. 131; SEQ. ID. NO. 132; SEQ. ID. NO. 133; SEQ. ID. NO. 135; SEQ. ID. NO. 136; SEQ. ID. NO. 137; SEQ. ID. NO. 138; SEQ. ID. NO. 143; SEQ. ID. NO. 144; SEQ. ID. NO. 145; SEQ. ID. NO. 146; SEQ. ID. NO. 147; SEQ. ID. NO. 148; and amino acid sequences at least 95% identical thereto.
Type:
Grant
Filed:
March 25, 2009
Date of Patent:
March 6, 2012
Assignees:
CSL Limited, The University of Melbourne
Inventors:
Bruce C. Ross, Ian G. Barr, Michelle A. Patterson, Catherine T. Agius, Linda J. Rothel, Mai B. Margetts, Dianna M. Hocking, Elizabeth A. Webb